Copy
Caladrius Biosciences Continues to Present at Multiple Upcoming May Conferences 



Caladrius Biosciences to Present at Multiple Upcoming May Conferences

 
BASKING RIDGE, N.J., May 9, 2016 – Caladrius Biosciences, Inc. (NASDAQ: CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select therapeutic development pipeline, announces today the Company’s leadership and experts will present at multiple upcoming May conferences.
 
Rebuilding the Failing Heart
  • Date and Time: Tuesday, May 10, 2016, 12:25 PM CEST
  • Website: www.cardiocentro.org/Rebuilding-the-Failing-Heart
  • Venue: Villa Sasso, Lugano, Switzerland
  • Topic: CD34-Positive Cells and the Rescue of the Failing Heart
  • Presenter: Douglas W. Losordo, MD, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
 
13th International Symposium on Stem Cell Therapy and Cardiovascular Innovations
  • Date and Time: Thursday, May 12, 2016, 4:15 PM CEST
  • Website: www.cardiovascularcelltherapy.com
  • Venue: Hospital General Universitario Gregorio Marañón, Madrid, Spain
  • Topic: Discoveries, Inventions & Breakdown
  • Discussant: Douglas W. Losordo, MD, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
     
Terrapinn World Stem Cells Regenerative Medicine Conference
  • Date and Time: Wednesday, May 18, 2016, 2:40 PM GMT
 
International Society for Cellular Therapy (ISCT) Annual Meeting 2016
 
Session 1
  • Date and Time: Thursday, May 26, 2016, 7:30 AM SGT
  • Topic: Innovation for Hire: Contract Development in Cell Therapy
  • Presenter: Ian Gaudet, PhD, Director, Innovation & Engineering of PCT
 
Session 2
  • Date and Time: Friday, May 27, 2016, 7:30 AM SGT
  • Panel: Managing Challenges to Achieve Optimal Cost of Goods
  • Panelist: Ian Gaudet, PhD, Director, Innovation & Engineering of PCT
 
Session 3
  • Date and Time: Friday, May 27, 2016, 10:45 AM SGT
  • Topic: A Case Study on Establishing a Global Commercial Enterprise for Cell Therapy Manufacturing
  • Presenter: George Goldberger, Vice President, Business Development of PCT
 
About Caladrius Biosciences
Caladrius Biosciences, Inc., through its subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry.  PCT works with its clients to overcome the fundamental challenges of cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. PCT and Hitachi Chemical Co. have entered into a strategic global collaboration to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise.  Around the core expertise of PCT, Caladrius strategically develops select product candidates, which currently includes an innovative therapy for type 1 diabetes based on a proprietary platform technology for immunomodulation. For more information, visit www.caladrius.com.

 
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 15, 2016, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.

 

  
Past Press Releases

May 5, 2016
Caladrius Biosciences Reports 2016 First Quarter Financial Results

April 18, 2016
Caladrius Reaches Agreement with Japanese Regulators on Development Plan for CD34 Cell Therapy for Critical Limb Ischemia

March 29, 2016
Caladrius Biosciences Announces First Subject Treated in CLBS03 Type 1 Diabetes Phase 2 Trial
Events

May 5, 2016
2016 First Quarter Financial Results Conference Call

April 28, 2016
Third International Regenerative Medicine Conference 2016

April 27, 2016
GTC Stem Cell Summit 2016
 
  
Contact Us

Investors:
LHA
Anne Marie Fields
Senior Vice President
Phone: +1-212-838-3777
Email: afields@lhai.com
 
 

Media:
Caladrius Biosciences, Inc.
Eric Powers
Director,
Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@caladrius.com
 
Copyright © 2016 Caladrius Biosciences, All rights reserved.
You are receiving this email because you opted in at our website or through analogous channel to receive announcements from Caladrius Biosciences, Inc.

Our mailing address is:
Caladrius Biosciences
106 Allen Road
4th Floor
Basking Ridge, NJ 07920

Want to change how you receive these emails?
Add us to your address book

You can update your preferences or unsubscribe from this list
 
 

Please visit our sites www.stockwatchindex.com and  www.swiresearch.com. We would appreciate if you could pass our newsletter on to your friends and colleagues. We always appreciate your feedback and comments.

 
Facebook
Twitter
LinkedIn
Google +
StockWatchIndex
 
StockWatchindex is a leading edge PR, Information Marketing and Research firm with a highly frequented web site www.stockwatchindex.com, its "Rise Above The Noise" newsletter and SWI Research site www.swiresearch.com published for the investment community. These services provide subscribers with information and detailed research reports on new, often undiscovered, but promising public companies. The QuickPicks section on the SWI site represents the consolidated opinions of carefully selected financial analysts and credible Wall Street firms that we respect and frequently sample. Our SWI QuickPicks  Ratings Report keeps subscribers informed about newly SWI initiated stocks and potential upgrades and downgrades in the QuickPicks section. We are not being compensated by the companies for the stocks in the QuickPicks section and do not necessarily hold positions in any of these stocks.. SWI's  "Portfolio Performance Report" periodically reports about the performance of the stocks that we have purchased for our portfolio, typically hold long and may be trading without notice.  Please do not miss the wealth of frequently updated news, research reports and other valuable information elsewhere on SWI, especially for the stocks on our WatchIndex page. Watch a full range of CEO and analyst interviews on our Strategic Partner site www.smallcapnation.com. StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise) of the information provided in the publications for its Stock Watch List, on its web sites or its newsletter. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, or the companies' themselves, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrants any results from use of the information. We have contracted with some of the companies we present on SWI or in the SWI Newsletter as public relations consultants to keep the market and especially our subscribers informed about the companies and may have been compensated in cash and/or stock and stock options, which may be considered a potential conflict of interest. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or in any of its other publications. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice.
Copyright © 2016 DynamicMarketConcepts, All rights reserved.


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp